Final Feasibility Study definition

Final Feasibility Study has the meaning specified in Section 7.9(d).
Sample 1
Final Feasibility Study. Is the Study that complies with the parameters described in Exhibit D. Net Profit Interest: Is the interest that corresponds to the VENDOR as established in Section Sixth of this Share Purchase Agreement, which is calculated according to Exhibit B. Interest on the Mining Right: The condition of assignee of 50% of the Mining Assignment Agreement entered into with the Assignor. The mining assignee condition grants Eastpac together with Minera Andes del Norte SAC the right to explore and exploit the Mining Right, as well as to exercise all the rights and obligations of the Mining Right titleholder during 10 years as of the date of executing the Mining Assignment Agreement extendable for equal periods of time.
Sample 1
Final Feasibility Study means the report which is the result of one or more comprehensive studies carried out by or on behalf of Kalimantan Gold and/or by a firm or corporation of good reputation with considerable experience in the preparation of such studies commissioned by or on behalf of Kalimantan Gold, the said study or studies to include an examination of the technical, economic and financial aspects of (a) developing and operating a Mine on any part of the Exploration Area; (b) the construction and operation of a Mill for the processing of ore produced from such Mine and (c) the sale of the processed product. The report must be of a standard sufficient to enable an informed decision to be made by the board of directors of Kalimantan Gold whether to proceed with the development of a Project and must be prepared in accordance with prevailing accepted mining industry standards and in a format which is capable of being used for the purpose of securing financing for a Project;
Sample 1

Examples of Final Feasibility Study in a sentence

  • The Final Feasibility Study Report incorporating comments, revisions and modifications suggested by NHAI shall be submitted within 15 days of receipt of comments from NHAI on draft feasibility study report.

  • The Final Feasibility Study Report incorporating comments, revisions and modifications suggested by NHIDCL shall be submitted within 15 days of receipt of comments from NHIDCL on draft feasibility study report.

  • The Final Feasibility Study Report incorporating comments, revisions and modifications suggested by State PWD / MoRTH shall be submitted within 15 days comments from State PWD, HP on draft feasibility study report.

  • Advancing the Final Feasibility Study for a stand-alone sulphide treating plant that is substantially larger than previously modelled and targeting significant annual gold production.

  • The Final Feasibility Study Report incorporating comments, revisions and modifications suggested by NHAI shall be submitted within 15 days of receipt comments from NHAI on draft feasibility study report.

  • The Final Feasibility Study Report incorporating comments, revisions and modifications suggested by PWD shall be submitted within 15 days of comments from PWD on draft feasibility study report.

  • The Final Feasibility Study Report incorporating comments, revisions and modifications suggested by State PWD/M/oRTH shall be submitted within 15 days of receipt of comments from State PWD on draft feasibility study report.

  • The Final Feasibility Study Report incorporating comments, revisions and modifications suggested by CE (P) Swastik (BRO) shall be submitted within 15 days of comments from CE (P) swastik (BRO) on draft feasibility study report.

  • The Final Feasibility Study Report incorporating comments, revisions and modifications suggested bythe Authority shall be submitted within 15 days of comments from the Authority on draft feasibility study report.

  • The Final Feasibility Study Report incorporating comments, revisions and modifications suggested by BRO shall be submitted within 15 days of receipt of comments from BRO on draft feasibility study report.


More Definitions of Final Feasibility Study

Final Feasibility Study means the report produced by Acquisition Member when the investigation of any Prospective Acquisition by Acquisition Member pursuant to Section 2.6 has been completed to the extent necessary to enable Company or any Joint Venture to fully assess the financial feasibility of, and the construction risks relating to, the Prospective Acquisition.
Sample 1
Final Feasibility Study means the report which is the result of one or more comprehensive studies carried out by or on behalf of NBG and/or by a firm or corporation of good reputation with considerable experience in the preparation of such studies commissioned by or on behalf of NBG, the said study or studies to include an examination of the technical, economic and financial aspects of (a) developing and operating a Mine on any part of the Exploration Area; (b) the construction and operation of a Mill for the processing of ore produced from such Mine and (c) the sale of the processed product. The report must be of a standard sufficient to enable an informed decision to be made by the board of directors of NBG whether to proceed with the development of a Project and must be prepared in accordance with prevailing accepted mining industry standards and in a format which is capable of being used for the purpose of securing financing for a Project;
Sample 1
Final Feasibility Study means the report produced by Westfield when the investigation of any proposed Development Works by Westfield pursuant to SECTION 2.6 has been completed to the extent necessary to enable Owner or a wholly-owned subsidiary of Owner or any Joint Venture to fully assess the financial feasibility of, and the construction risks relating to, the proposed Development Works.
Sample 1
Final Feasibility Study means the report produced by Westfield or a member of the Westfield Group, and approved by Owner or its Affiliate, in accordance with the terms of the Development Framework Agreement.
Sample 1

Related to Final Feasibility Study

  • Feasibility Study means the evaluation and analysis of the potential of a project, which aims at supporting the process of decision-making by objectively and rationally uncovering its strengths and weaknesses, opportunities and threats, as well as identifying the resources required to carry it through and ultimately its prospects for success;

  • Interconnection Feasibility Study means either a Generation Interconnection Feasibility Study or Transmission Interconnection Feasibility Study.

  • Phase I Study means a study in humans which provides for the first introduction into humans of a product, conducted in healthy volunteers or patients to obtain information on product safety, tolerability, pharmacological activity or pharmacokinetics, as more fully defined in 21 C.F.R. § 312.21(a) (or the non-United States equivalent thereof).

  • Phase I Clinical Study means, as to a particular Licensed Product, an initial clinical study in humans with the purpose of assessing the Licensed Product’s safety, tolerability, toxicity, pharmacokinetics or other pharmacological properties.

  • Phase II Study means a study in humans of the safety, dose ranging or efficacy of a product, as further defined in 21 C.F.R. § 312.21(b) (or the equivalent thereof outside the United States).

  • Study Completion means the database for the Study has been locked and all Essential Documents have been provided to the Sponsor, including a copy of the letter from the Reviewing HREC acknowledging receipt of the final report and/or closure letter from the Principal Investigator.

  • Phase II Clinical Study means a human clinical study of a product initiated to determine the safety and efficacy in the target patient population, as described 21 C.F.R. 312.21(b).

  • Phase II Trial means a clinical trial of a Licensed Product, designated as a Phase II Trial and the principal purpose of which is to make a preliminary determination that such Licensed Product is safe and active in a patient population for its intended use and is designed to obtain sufficient information about such Licensed Product’s efficacy to permit the design of a Phase III Trial(s), and generally consistent with 21 CFR § 312.21(b). For purposes of this definition, Phase II trial shall specifically exclude expansion cohorts from Phase I Trial(s).

  • Development Report means a written account of Licensee’s progress under the Development Plan having at least the information specified on Appendix B to this Agreement, and shall be sent to the address specified on Appendix B.

  • Phase I Trial means a clinical trial of a Licensed Product in human patients designated as a Phase I Trial and conducted primarily for the purpose of determining the safety of and/or the metabolism and pharmacologic actions of the Licensed Product in humans, as described under 21 CFR § 312.21(a) (as hereafter modified or amended) and any of its foreign equivalents. For purposes of this definition, Phase I Trial shall specifically exclude trials in healthy volunteers.

  • Phase IIb Clinical Trial means a clinical trial of a Product on sufficient numbers of patients that is designed to provide a preliminary determination of safety and efficacy of such Product in the target patient population over a range of doses and dose regimens.

  • Phase I Clinical Trial means a human clinical trial that is intended to initially evaluate the safety and/or pharmacological effect of a Product in subjects or that would otherwise satisfy requirements of 21 C.F.R. 312.21(a), or its foreign equivalent.

  • Phase III Study means a human clinical trial that is prospectively designed to demonstrate statistically whether a product is safe and effective for use in humans in a manner sufficient to obtain regulatory approval to market such product in patients having the disease or condition being studied as described in 21 C.F.R. § 312.21(c) (FDCA), as amended from time to time, and the foreign equivalent thereof.

  • Phase 2 Clinical Trial means a human clinical trial of a product in any country that would satisfy the requirements of 21 C.F.R. 312.21(b) and is intended to explore a variety of doses, dose response, and duration of effect, and to generate initial evidence of clinical safety and activity in a target patient population, or a similar clinical study prescribed by the relevant Regulatory Authorities in a country other than the United States.

  • Phase III Clinical Study means a pivotal Clinical Study, the results of which could be used to establish safety and efficacy of a Licensed Product in the Field as a basis for Regulatory Approval or that would otherwise satisfy requirements of 21 CFR 312.21(c), or its foreign equivalent.

  • Phase II Clinical Trial means a study in humans of the safety, dose ranging and efficacy of a product, which is prospectively designed to generate sufficient data (if successful) to commence a Phase III Clinical Trial or to file for accelerated approval, or otherwise consistent with the requirements of U.S. 21 C.F.R. §312.21(b) or its foreign equivalents.

  • Development Phase means the period before a vehicle type is type approved.

  • Study means the investigation to be conducted in accordance with the Protocol.

  • Phase 4 Clinical Trial means a Clinical Trial of a Product conducted after Regulatory Approval of such Product has been obtained from an appropriate Regulatory Authority, which trial is (a) conducted voluntarily by a Party to enhance marketing or scientific knowledge of the Product, or (b) conducted due to a request or requirement of a Regulatory Authority.

  • Phase 1 means the first implementation phase of this section, beginning June 1, 2018 and ending May 31, 2022.

  • Clinical Study or “Clinical Studies” means a Phase 0 Xxxxx, Xxxxx 0 Xxxxx, Xxxxx 0 Trial or Phase 4 Trial, or such other study in humans that is conducted in accordance with good clinical practices and is designed to generate data in support or maintenance of an NDA, MAA or other similar marketing application.

  • Phase III means Phase I (or Phase I/II), Phase II (or Phase II/III) and Phase III clinical trials, respectively, in each case as prescribed by applicable FDA IND Regulations, or any corresponding foreign statutes, rules or regulations.

  • Phase 1 Clinical Trial means a Clinical Trial of a Product on sufficient numbers of normal volunteers and/or patients that is designed to establish that such Product is safe for its intended use and to support its continued testing in Phase 2 Clinical Trials. For purposes of this Agreement, ‘initiation’ of a Phase 1 Clinical Trial for a Product means the first dosing of such Product in a human subject in a Phase 1 Clinical Trial.

  • Phase III Trial means a Clinical Trial of an investigational product in subjects that incorporates accepted endpoints for confirmation of statistical significance of efficacy and safety with the aim to generate data and results that can be submitted to obtain Regulatory Approval as described in 21 C.F.R. 312.21(c), or a comparable Clinical Trial prescribed by the relevant Regulatory Authority in a country other than the United States.

  • Phase 3 Clinical Trial means a pivotal clinical trial in humans performed to gain evidence with statistical significance of the efficacy of a product in a target population, and to obtain expanded evidence of safety for such product that is needed to evaluate the overall benefit-risk relationship of such product, to form the basis for approval of an NDA and to provide an adequate basis for physician labeling, as described in 21 C.F.R. § 312.21(c) or the corresponding regulation in jurisdictions other than the United States.